Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 1023.00, up by 4.20 points or 0.41% from its previous closing of Rs. 1018.80 on the BSE.

The scrip opened at Rs. 1028.00 and has touched a high and low of Rs. 1029.80 and Rs. 1019.50 respectively. So far 14,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1085.40 on 30-May-2013 and a 52 week low of Rs. 554.00 on 05-Jun-2012.

Last one week high and low of the scrip stood at Rs. 1085.40 and Rs. 990.00 respectively. The current market cap of the company is Rs. 1,05,936.00 crore.

The promoters holding in the company stood at 63.68% while Institutions and Non-Institutions held 26.00% and 10.32% respectively.

Sun Pharmaceutical Industries has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Depo-Testosterone Injection, Testosterone Cypionate Injection USP, 100 mg/ml and 200mg/ml.

This generic Testosterone Cypionate Injection USP, 100 mg/mL and 200mg/mL is therapeutically equivalent to Depo-Testosterone Injection of Pfizer Inc and is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. As per April-2013, IMS MAT, the product had annual revenues of approximately $130 million in the US.

Sun Pharmaceuticals Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.